Allergy and Respiratory Diseases, Department of Internal Medicine, University of Genoa, Genoa, Italy.
PLoS One. 2012;7(6):e37980. doi: 10.1371/journal.pone.0037980. Epub 2012 Jun 19.
Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is involved in the activation pathways of T lymphocytes. It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be down regulated by immunotherapy.
to assess the effects on CTLA-4 of venom immunotherapy, given with different induction protocols: conventional (6 weeks), rush (3 days) or ultra rush (1 day).
Sera from patients with hymenoptera allergy were collected at baseline and at the end of the induction phase. CTLA-4 and IL-10 were assayed in the same samples. A subset of patients were assayed also after 12 months of VIT maintenance.
Ninety-four patients were studied. Of them, 50 underwent the conventional induction, 20 the rush and 24 the ultra-rush. Soluble CTLA-4 was detectable in all patients at baseline, and significantly decreased at the end of the induction, irrespective of its duration. Of note, a significant decrease of sCTLA-4 could be seen already at 24 hours. In parallel, IL-10 significantly increased at the end of the induction. At 12 months, sCTLA-4 remained low, whereas IL-10 returned to the baseline values.
Serum CTLA4 is an early marker of the immunological effects of venom immunotherapy, and its changes persist after one year of maintenance treatment.
细胞毒性 T 淋巴细胞相关抗原 4(CTLA-4)参与 T 淋巴细胞的激活途径。已经表明,变应原性蜂类过敏患者的循环 CTLA-4 水平升高,并且可以通过免疫疗法下调。
评估不同诱导方案(常规(6 周)、快速(3 天)或超快速(1 天))下毒液免疫疗法对 CTLA-4 的影响。
在基线和诱导阶段结束时收集变应原性蜂类过敏患者的血清。在相同的样本中检测 CTLA-4 和 IL-10。一小部分患者在 VIT 维持 12 个月后也进行了检测。
共研究了 94 名患者。其中,50 名患者接受常规诱导,20 名患者接受快速诱导,24 名患者接受超快速诱导。所有患者在基线时均可检测到可溶性 CTLA-4,并且无论诱导持续时间如何,诱导结束时均显著降低。值得注意的是,在 24 小时即可观察到 sCTLA-4 的显著下降。同时,IL-10 在诱导结束时显著增加。在 12 个月时,sCTLA-4 仍然较低,而 IL-10 恢复到基线值。
血清 CTLA4 是毒液免疫疗法免疫效应的早期标志物,并且在维持治疗 1 年后其变化仍然存在。